Mestastop Solutions Submits MSAP031 for FDA Phase 2 Trials
The biotechnology firm is pursuing United States regulatory approval for a drug candidate designed to delay cancer metastasis.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Should more investment focus on repurposing existing drugs to treat cancer metastasis?
Bengaluru-based startup Mestastop Solutions has initiated a Phase 2 Investigational New Drug application with the U.S. FDA for its cancer candidate, MSAP031. The firm has contracted New Jersey-based Aleon Pharma International to manage the regulatory submission process.
Why it matters
Metastasis is responsible for approximately 90% of cancer-related deaths worldwide. By focusing on delaying this spread, the drug candidate aims to address the most lethal aspect of cancer progression.
MSAP031 is a clinical candidate identified by the MetGuard platform that is already approved for Phase 2 trials by the Central Drugs Standard Control Organisation in India. Retrospective analyses suggest the repurposed drug improves patient survival rates.
The players
Mestastop Solutions
A biotechnology startup based in Bengaluru that uses its proprietary MetGuard platform to identify drug candidates.
Aleon Pharma International
A company headquartered in Parsippany, New Jersey, that manages complex regulatory processes for pharmaceutical firms.
U.S. Food and Drug Administration
The federal agency responsible for regulating new drug applications and clinical research standards in the United States.
Central Drugs Standard Control Organisation
The national regulatory body in India that oversees clinical trial approvals and drug manufacturing standards.
The details
Aleon Pharma International is conducting a gap assessment of the nonclinical, clinical, and CMC data to ensure compliance with 21 CFR Part 312 regulations. This collaboration allows the startup to navigate complex U.S. clinical requirements as they prepare for a Phase 2 study.
Timeline
October 31, 2026: The IND application process is initiated.
Health Landscape
The filing follows the strict regulatory pathway defined by 21 CFR Part 312 to move an experimental candidate into American clinical trials. This reflects the broader industry standard of utilizing rigorous clinical oversight to validate experimental metastasis-delaying therapies.
If the clinical trials are successful and the drug reaches the market, it could provide new treatment options for patients facing advanced cancer stages. Currently, the process remains in the regulatory filing stage with no immediate impact on available therapies.
The takeaway
The move to pursue FDA approval marks a significant step in scaling a treatment developed in India for the international market. Future clinical studies will determine if the early survival benefits observed in retrospective analyses hold up in a controlled U.S. research environment.
Further reading
Learn more about ongoing developments in oncological research at the Cancer section.
Source note: This article includes information reported by Biospectrumindia.
Live Poll
Should more investment focus on repurposing existing drugs to treat cancer metastasis?
